Vital Signs - In Acquisitions We Trust


Regular Price: USD 1,500.00

Special Price USD 1,050.00

30% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,050.00


Be the first to review this product

This issue of Vital Signs, released on February 12, 2007, provides a strategic overview of important acquisition criteria for M&A activities in the pharmaceutical industry. Additionally, an emerging company profile is provided for AmpliMed Corporation, a clinical stage pharmaceutical company specializing in small molecule oncology drugs. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of January 29 - February 2, 2007.

Table of Contents

Vital Signs - In Acquisitions We TrustVital Signs: 12 February 2007This week's issue:

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.